Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10873133 | 1.00 | KDM4E (0.36) | KDM4EALDH1A1MTNR1AMTNR1BLMNA | |
| SCHEMBL10917925 | 0.82 | — | — | |
| SCHEMBL8634789 | 0.82 | CTRB1 (0.35) | CTRB1 | |
| SCHEMBL553861 | 0.82 | CTRB1 (0.35) | CTRB1 | |
| SCHEMBL3596240 | 0.82 | CTRB1 (0.35) | CTRB1 | |
| SCHEMBL7976755 | 0.81 | KDM4E (0.41) | KDM4EMTNR1AMTNR1BLMNAPOLB | |
| SCHEMBL7403136 | 0.81 | GAA (0.37) | — | |
| SCHEMBL7801965 | 0.81 | GAA (0.37) | — | |
| SCHEMBL7403132 | 0.81 | GAA (0.37) | — | |
| SCHEMBL6849200 | 0.81 | KDM4E (0.41) | KDM4EMTNR1AMTNR1BLMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1776382-B1 | A PROCESS FOR PRODUCING IRON SUCCINYL CASEIN AND ACETYL-ASPARTATE IRON CASEIN COMPLEXES AND USE THEREOF IN PHARMACEUTICAL MIXTURES | BIOFER SPA (IT) | 2008-12-03 | — | — | EP | claimed |
| EP-1776382-A1 | A PROCESS FOR PRODUCING IRON SUCCINYL CASEIN AND ACETYL-ASPARTATE IRON CASEIN COMPLEXES AND USE THEREOF IN PHARMACEUTICAL MIXTURES | Biofer S.p.A. (IT) | 2007-04-25 | — | — | EP | claimed |
| WO-2006021843-A1 | A PROCESS FOR PRODUCING IRON SUCCINYL CASEIN AND ACETYL-ASPARTATE IRON CASEIN COMPLEXES AND USE THEREOF IN PHARMACEUTICAL MIXTURES | BIOFER S.P.A. (IT) | 2006-03-02 | — | — | WO | claimed |
| US-12145130-B2 | Multimodal adsorption medium with multimodal ligands, method for the preparation and use thereof | SARTORIUS STEDIM BIOTECH GMBH (DE) | 2024-11-19 | — | — | US | disclosed |
| CN-118063491-A | Imide catalyst auxiliary agent, polyimide film and preparation method | 中国科学院化学研究所 | 2024-05-24 | — | — | CN | disclosed |
| US-20220055015-A1 | MULTIMODAL ADSORPTION MEDIUM WITH MULTIMODAL LIGANDS, METHOD FOR THE PREPARATION AND USE THEREOF | SARTORIUS STEDIM BIOTECH GMBH (DE) | 2022-02-24 | — | — | US | disclosed |
| EP-3034512-B1 | A process for producing iron (III) casein N-acetyl-aspartylated complexes and use thereof in pharmaceutical compositions | TSETI IOULIA (GR) | 2017-12-06 | — | — | EP | disclosed |
| US-20170340747-A1 | PROCESS FOR PRODUCING IRON (III) CASEIN N-ACETYL-ASPARTYLATED COMPLEXES AND USE THEREOF IN PHARMACEUTICAL COMPOSITIONS | TSETI IOULIA (GR) | 2017-11-30 | — | — | US | disclosed |
| WO-2016096203-A1 | A PROCESS FOR PRODUCING IRON (III) CASEIN N-ACETYL-ASPARTYLATED COMPLEXES AND USE THEREOF IN PHARMACEUTICAL COMPOSITIONS | TSETI IOULIA (GR) | 2016-06-23 | — | — | WO | disclosed |
| EP-3034512-A1 | A process for producing iron (III) casein N-acetyl-aspartylated complexes and use thereof in pharmaceutical compositions | Tseti, Ioulia (GR) | 2016-06-22 | — | — | EP | disclosed |
| CN-101142181-B | Process for the preparation of enantiomerically pure 4-pyrrolidinophenylbenzyl ether derivatives | HOFFMANN LA ROCHE | 2011-05-04 | — | — | CN | disclosed |
| EP-1776382-B1 | A PROCESS FOR PRODUCING IRON SUCCINYL CASEIN AND ACETYL-ASPARTATE IRON CASEIN COMPLEXES AND USE THEREOF IN PHARMACEUTICAL MIXTURES | BIOFER SPA (IT) | 2008-12-03 | — | — | EP | disclosed |
| CN-101142181-A | Process for the preparation of enantiomerically pure 4-pyrrolidinophenylbenzyl ether derivatives | HOFFMANN LA ROCHE (CH) | 2008-03-12 | — | — | CN | disclosed |
| EP-1776382-A1 | A PROCESS FOR PRODUCING IRON SUCCINYL CASEIN AND ACETYL-ASPARTATE IRON CASEIN COMPLEXES AND USE THEREOF IN PHARMACEUTICAL MIXTURES | Biofer S.p.A. (IT) | 2007-04-25 | — | — | EP | disclosed |
| EP-1236716-B1 | Methods for making optically active 3-aminopyrrolidine-2,5-dione derivative and optically active 3-aminopyrrolidine derivative | TORAY FINECHEMICALS CO LTD (JP) | 2007-04-11 | — | — | EP | disclosed |
| WO-2006021843-A1 | A PROCESS FOR PRODUCING IRON SUCCINYL CASEIN AND ACETYL-ASPARTATE IRON CASEIN COMPLEXES AND USE THEREOF IN PHARMACEUTICAL MIXTURES | BIOFER S.P.A. (IT) | 2006-03-02 | — | — | WO | disclosed |
| EP-1236716-A1 | Methods for making optically active 3-aminopyrrolidine-2,5-dione derivative and optically active 3-aminopyrrolidine derivative | TORAY INDUSTRIES, INC. (JP) | 2002-09-04 | — | — | EP | disclosed |
| US-6348600-B1 | CYCLIZING OPTICALLY ACTIVE ASPARAGINE ESTER DERIVATIVE OR ACID SALT THEREOF BY DISSOLVING COMPOUND IN SOLVENT | TORAY INDUSTRIES, INC. (JP) | 2002-02-19 | — | — | US | disclosed |
| US-4593045-A | N-acetyl-L-aspartyl taurine useful as hypertensive agent | Societe a Responsabilite Limite dite: B.F.B. Estudes et Recherches Experimentales (FR) | 1986-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12145130-B2 | Multimodal adsorption medium with multimodal ligands, method for the preparation and use thereof | NEFM, ADM2, IGFBP4 | KDM4E 4584/4885ALDH1A1 3144/4885MTNR1A 1230/4885 |
| US-20220055015-A1 | MULTIMODAL ADSORPTION MEDIUM WITH MULTIMODAL LIGANDS, METHOD FOR THE PREPARATION AND USE THEREOF | NEFM, ADM2, IGFBP4 | KDM4E 4584/4885ALDH1A1 3144/4885MTNR1A 1230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.